SUNNYVALE, Calif. , Sept. 5, 2019 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that it will showcase its industry-leading motion-synchronization cancer treatment technologies at the upcoming American Society for Radiation Oncology (ASTRO) Annual Meeting taking place
World's Largest Annual Gathering of the Radiation Oncology Community Provides Multiple Opportunities to Learn about the CyberKnife® M6™ Series and the TomoTherapy® H™ Series Systems SUNNYVALE, Calif. and ATLANTA , Sept. 22, 2013 /PRNewswire/ -- ASTRO 2013 -- Accuray Incorporated (Nasdaq: ARAY)
Conference Presentation Highlights Monte Carlo Dose Calculation Benefits in Precision Radiation Delivery for Lung Cancer SUNNYVALE, Calif. , Aug. 31 /PRNewswire-FirstCall/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that the company will
Innovations in Hardware and Software Solutions Reinforce the Benefits of Accuray Systems in Treating a Wide Range of Cancer Cases SUNNYVALE, Calif. , May 3, 2017 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the company will highlight its portfolio of radiation therapy
SUNNYVALE, Calif. , April 23, 2015 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY) announced today that the company will highlight new CyberKnife ® and TomoTherapy ® technologies at the European Society for Therapeutic Radiology and Oncology (ESTRO) meeting, booth #2100, in Barcelona, Spain ,
Innovations in Hardware and Software Solutions and New Clinical Data Reinforce the Benefits of Accuray Systems in Treating a Wide Range of Cancer Cases SUNNYVALE, Calif. , Sept. 22, 2016 /PRNewswire/ -- New data on the Accuray (NASDAQ: ARAY) CyberKnife® and TomoTherapy® Systems will be shared by
SUNNYVALE, Calif., Oct 02, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, today announced that it will provide a live webcast for its first ever Analyst Day event, and media and investors are invited to
- Phase III, randomized controlled trial results highlight patient reported outcomes at 10 years'follow-up - TomoTherapy delivered hypofractionated radiotherapy was superior to conventional radiotherapy in maintaining patients' heart and lung functioning, enabling them to more easily perform daily
Combined Company Showcases Breadth and Depth of Treatment Capabilities, Delivering Personalized Radiation Oncology Solutions MIAMI and SUNNYVALE, Calif., Oct. 3, 2011 /PRNewswire via COMTEX/ -- American Society for Radiation Oncology (ASTRO) 53 rd Annual Meeting -- Accuray Incorporated (Nasdaq:
New VoLO™ Technology Delivers Greater Efficiency and Flexibility in Complex Treatment Planning; Demonstrates Accuray's Ongoing Commitment to Advancing Radiation Oncology SUNNYVALE, Calif. , May 9, 2012 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company,
*The quarterly and year-end results reported herein were subsequently revised for adjustments that were immaterial, individually and in the aggregate. The revised quarterly and year-end results are included in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the "SEC") on August 25, 2020, and are accessible on our website at https://investors.accuray.com/financial-information/sec-filings and on the SEC's website at www.sec.gov.
